Carl Zeiss Meditec (ETR:AFX) Stock Price Down 1.3% - What's Next?

Key Points

• Shares fell 1.3% to €25.04 on Monday, with ~186,111 shares traded — about 97% above the stock's average daily volume.
• The stock is trading well below its 50‑day (€31.72) and 200‑day (€39.23) moving averages; market cap is roughly $2.33 billion with a PE ratio of 13.38.
• Carl Zeiss Meditec is a medical‑technology company focused on Ophthalmology and Microsurgery, supplying diagnostic and treatment devices for eye diseases.

Carl Zeiss Meditec AG (ETR:AFX - )'s stock price was down 1.3% on Monday . The stock traded as low as €25.04 and last traded at €25.04. Approximately 186,111 shares changed hands during mid-day trading, an increase of 97% from the average daily volume of 94,405 shares. The stock had previously closed at €25.38.

Carl Zeiss Meditec Trading Down 1.3%

The stock has a market cap of $2.33 billion, a PE ratio of 13.38, a price-to-earnings-growth ratio of 2.83 and a beta of 1.44. The company's 50-day moving average price is €31.72 and its 200 day moving average price is €39.23. The company has a debt-to-equity ratio of 28.70, a quick ratio of 2.47 and a current ratio of 2.35.

Carl Zeiss Meditec Company Profile

Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, such as ametropia (refraction), cataracts, glaucoma, and renital disorders. This segment also provides devices for general ophthalmological examination and care, including slit lamps, refractometers, tonometers, optical coherence tomography devices, and fundus cameras; and devices for functional diagnostics (perimeters), as well as digital products for storage, evaluation, and sharing of clinical data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.